BIMINI Biotech is developing first-in-class small-molecule modulators of the Wiskott–Aldrich Syndrome Protein (WASP) pathway, a key regulator of immune cell cytoskeleton dynamics with significant therapeutic relevance in hematologic cancers and immune disorders. We are based in Leiden (The Netherlands), supported funding from UNIIQ, LEH, Innovation quarter capital and Torrey Pines Investment (US).

Our lead program targets acute myeloid leukemia (AML), a high-unmet-need market. BIMINI’s approach aims to selectively disrupt leukemic cell survival through cytoskeletal modulation. We have demonstrated strong preclinical activity of the compounds in hematologic cancers and also identified potential application in autoimmune disorders.

We are currently in the lead optimization stage and aim to start IND enabling work in 2027. Therefore, we are currently raising a series A of €10M to bridge the gap for our WASP modulator program towards FIH studies. The development strategy is to advance our assets to Phase 1/2 clinical proof-of-concept.